This is how the patch works: it emits a small amount of positive charge, which attracts the negatively-charged FABP3 protein, a biomarker for heart attacks. If analysis shows an increased level of the protein, a heart attack is underway.
Despite clinical validation, not everyone is convinced of the patch’s effectiveness. “No single biomarker can be 100 per cent reliable,” says U Natarajan, head of adult cardiology, Amrita Institute of Medical Sciences, Kochi. “When it’s normal, it may truly mean absence of disease, but when abnormal, it may not necessarily mean the presence of disease.”
The analysis of FABP3 needs a blood sample, says Natarajan. So when “the young genius says he can non-invasively assess elevation of this protein, it’s quite amazing. But he is oversimplifying things,” says Natarajan. Nevertheless, Manoj’s vision for the future does hold promise, he adds.